John Petkau

TL;DR: Refined descriptors that include consideration of disease activity (based on clinical relapse rate and imaging findings) and disease progression are proposed and strategies for future research to better define phenotypes are outlined.

TL;DR: A composite measure encompassing the major clinical dimensions of arm, leg and cognitive function was identified and termed the multiple sclerosis functional composite (MSFC), suggesting that the MSFC is more sensitive to change than the EDSS.

TL;DR: Exposure to interferon beta was not associated with a statistically significant difference in the hazard of reaching an EDSS score of 6 when either the contemporary control cohort or the historical control cohort was considered, and propensity score adjustment did not substantially change the results.

TL;DR: This study confirmed the limited correlation between clinical manifestations and T2 burden of disease (BOD) but revealed an important plateauing relationship between T2 BOD and disability.

TL;DR: In cases of sustained high-titre NAb positivity and/or lack of MxA bioactivity, a switch to a non-interferon-beta therapy should be considered and in patients who are doing poorly clinically, therapyShould be switched irrespective of NAb or Mx a bioactivity.